TCR-T cells directed against TP53 mutations, for instance, are now the subject of clinical investigation in breast cancer, showing a time-limited response in a case with tumor progression after 6 months, relating to a loss of MHC class I expression [40,41]. The gene discussed is TP53; the disease is neoplasm.